Exact Sciences Corporation
Exact Sciences Corporation (EXAS) Revenue
Annual & quarterly revenue history · segment & region breakdown
EXAS · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsExact Sciences Corporation trailing twelve-month (TTM) revenue is $3.25B, an increase of 17.69% year-over-year from $3.25B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $3.25B | +$0.49B | +17.69% |
| 2024-12-31 | $2.76B | +$0.26B | +10.37% |
| 2023-12-31 | $2.50B | +$0.42B | +19.93% |
| 2022-12-31 | $2.08B | +$0.32B | +17.95% |
| 2021-12-31 | $1.77B | +$0.28B | +18.49% |
| 2020-12-31 | $1.49B | +$0.62B | +70.19% |
| 2019-12-31 | $0.88B | +$0.42B | +92.82% |
| 2018-12-31 | $0.45B | +$0.19B | +70.86% |
| 2017-12-31 | $0.27B | +$0.17B | +167.66% |
| 2016-12-31 | $0.10B | +$0.06B | +151.99% |
Compare revenue vs peers
Medical - Diagnostics & ResearchCompare EXAS revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Exact Sciences Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Exact Sciences Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Exact Sciences Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
EXAS revenue · 4 questionsEXAS's trailing twelve-month (TTM) revenue is $3.25B. That is an increase of 17.69% year-over-year from $3.25B in FY2025.
▸ Source: FMP · Exact Sciences Corporation SEC filings · GAAP · Exact Sciences Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026